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Abstract
Background: Caesarean section before labor or before ruptured membranes ("elective caesarean
section", or ECS) has been introduced as an intervention for preventing mother-to-child
transmission (MTCT) of hepatitis B virus (HBV). Currently, no evidence that ECS versus vaginal
delivery reduces the rate of MTCT of HBV has been generally provided. The aim of this review is
to assess, from randomized control trails (RCTs), the efficacy and safety of ECS versus vaginal
delivery in preventing mother-to-child HBV transmission.
Results: We searched Cochrane Pregnancy and Childbirth Group's Trials Register (January, 2008),
the Cochrane Central Register of Controlled Trials (the Cochrane Library 2008, issue 1), PubMed
(1950 to 2008), EMBASE (1974 to 2008), Chinese Biomedical Literature Database (CBM) (1975 to
2008), China National Knowledge Infrastructure (CNKI) (1979 to 2008), VIP database (1989 to
2008), as well as reference lists of relevant studies. Finally, four randomized trails involving 789
people were included. Based on meta-analysis, There was strong evidence that ECS versus vaginal
delivery could effectively reduce the rate of MTCT of HBV (ECS: 10.5%; vaginal delivery: 28.0%).
The difference between the two groups (ECS versus vaginal delivery) had statistical significance (RR
0.41, 95% CI 0.28 to 0.60, P < 0.000001). No data regarding maternal morbidity or infant morbidity
according to mode of delivery were available.
Conclusion:  ECS appears to be effective in preventing MTCT of HBV and no postpartum
morbidity (PPM) was reported. However, the conclusions of this review must be considered with
great caution due to high risk of bias in each included study (graded C).
Background
Description of the condition
Hepatitis B is a major global problem. More than two bil-
lion people alive today have been infected worldwide [1]
and approximately 350 million people are chronically
infected with hepatitis B virus (HBV) [2,3]. Chronic hepa-
titis B (CHB) is associated with serious complications,
including liver failure, cirrhosis, and hepatocellular carci-
noma [4-6]. Each year more than one million patients
with CHB worldwide die from these diseases [1].
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Mother-to-child transmission(MTCT) of HBV is one of the
most important causes of chronic HBV infection [7-9] and
remains one serious problem despite passive immuniza-
tion (hepatitis B immune globulin at birth) and active
immunization (hepatitis B vaccination according to the
standard 3-dose schedule). MTCT may occur prenatally,
during delivery, or postpartum. Currently, a series of
measures have been taken to prevent both prenatal and
postpartum routes of transmission with progress being
achieved to some extent. However, with regard to MTCT
of HBV during delivery, disagreements still exist on the
issue of whether different mode of delivery (mainly cae-
sarean section versus vaginal delivery) will affect the risk of
mother-to-child HBV transmission [10,11].
Description of the intervention
Of the cases of MTCT of HBV, a large population occur
during the intrapartum period. Underlying mechanisms
may include transfusion of the mother's blood to the fetus
during labor contractions, infection after the rupture of
membranes, and direct contact of the fetus with infected
secretions or blood from the maternal genital tract [12-
16]. As elective caesarean section (ECS) is performed
before the onset of labor or the rupture of membranes, it
could effectively avoid the disbenefits described above.
Therefore, ECS might reduce the risk of MTCT of HBV
(compared with vaginal delivery or cesarean section after
onset of labor or after rupture of membranes).
It is well known that, in the absence of HBV infection, ECS
is related to increased risks of maternal and infant mor-
bidity [17-19]. In a population of HBV-infected women,
the procedure would be expected to be associated with the
same or greater deleterious effects on both mother and
infant. For instance, surgical delivery would be expected
to increase the risk of fever, endometritis, and hemorrhage
and severe anemia among women. Commonly, Infants
born by ECS at term are at increased risk for developing
respiratory disorders compared with those born by vagi-
nal delivery. However, although the risk of neonatal respi-
ratory morbidity is higher, the number of affected infants
is small [20]. In addition to respiratory morbidity (respi-
ratory distress syndrome, transient tachypnea of the new-
born), an increased risk of lacerations of newborn skin is
also of concern with surgical delivery.
Why it is important to do this overview
Given the uncertainty of findings from current studies,
what is more, HBV-infected pregnant women must be
provided with available information with which to make
informed decisions regarding ECS and other options to
prevent transmission of infection to their children, we aim
to determine if there is any evidence from randomized
controlled trials (RCTs) that offering ECS to mothers who
are infected with HBV affects the risk of MTCT of HBV.
Results
Description of studies
Studies identified
A total of 942 studies were identified by the searches. No
unpublished studies or other information was obtained
from contact with WHO and individual researchers. By
scanning titles and abstracts of the 942 studies, 927 stud-
ies, including overlapped studies, reviews, case reports
and meta analyses, were excluded. After referring to full
texts, 11 studies were excluded upon further scrutiny due
to the following reasons: 7 studies made HBV-infected
women with positive hepatitis B surface antigen (HBsAg)
and/or hepatitis B e antigen (HBeAg) as their participant
criteria; 3 studies had other interventions potentially
impacting the outcome; 1 study did not provide data to
meet the outcome criteria. Finally, we included 4 studies,
involving 789 people, which were all performed in china.
Among them, 1 were published in English [21] (Lee
1988), 3 in Chinese (Ji 2002, Wang 2004, Liu 2008, avail-
able only by searching the database of CNKI). Apart from
Chinese and English, we did not search citations in other
languages.
Designs of included studies
All the included studies were of a parallel design, single
centre and had a control group.
Participants of included studies
Numbers of participants of the individual studies ranged
from 97 to 244 with a total of 789 participants included
in this review. All of them were HBV-infected pregnant
women with HBV DNA-positive in sera of blood. The
baseline characteristics (including the age, race, gravidity,
parity, pregnant week, disease duration, and severity of
disease, etc) were similar in the two groups (P > 0.05).
Interventions of included studies
ECS was made as the intervention group, and vaginal
delivery as the control group in each of the four studies.
Outcomes of included studies
None of the four studies reported the maternal morbidity
or infant morbidity associated with ECS. The common
outcome reported was the positive rate of HBV DNA in
neonates under different mode of delivery (ECS versus
vaginal delivery).
Methodological quality
Randomization
All the four studies mentioned "random", "randomize" or
"randomized", but did not give a clear description of the
randomization procedure.Virology Journal 2008, 5:100 http://www.virologyj.com/content/5/1/100
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Allocation concealment
No allocation concealment was used in each of the four
studies
Blinding
No blind was used in each of the four studies
Description of withdrawals, dropouts, losses of follow up and 
intention-to-treat analysis
Neither of the included studies mentioned withdrawals,
dropouts, losses of follow up or performed any intention-
to-treat analysis.
According to the quality criteria listed above, we consid-
ered each included study was at high risk of bias and
graded as category C.
Effects of interventions
Assessment of the efficacy of ECS versus vaginal delivery for 
preventing MTCT of HBV
Four studies demonstrated the efficacy of ECS compared
to vaginal delivery for the prevention of MTCT of HBV.
According to chi-squared statistic and I square (I2), the
results of the four studies showed no statistical heteroge-
neity (p = 0.48.I2 = 0%). So we used fixed effect model for
meta-analysis. After synthesizing the results, we found out
that the rate of MTCT of HBV according to mode of deliv-
ery differed significantly (ECS: 10.5%; vaginal delivery:
28.0%). The difference between the two groups (ECS ver-
sus vaginal delivery) had statistical significance (RR 0.41,
95% CI 0.28 to 0.60, P < 0.000001) (Figure 1). Therefore,
in comparison to vaginal delivery, ECS is more efficacious
for the prevention of MTCT of HBV.
Subgroup analyses
Of the four included studies, one trail performed the
detection of HBV DNA in neonate's umbilical blood,
while other three trails in neonate's peripheral blood. So
subgroup analysis was carried out under the two circum-
stances. The trend towards elevated rate of MTCT of HBV
in the ECS group compared to vaginal delivery group with
HBV DNA detected in neonate's umbilical blood (RR
0.50, 95% CI 0.26 to 0.95) was similar to studies with
HBV DNA detected in neonate's peripheral blood (RR
0.37, 95% CI 0.24 to 0.59) (Figure 2).
Sensitivity analyses
We did not carry out any of the planned sensitivity analy-
ses as no unpublished studies were found and all included
studies were at high risk of bias (graded C).
Assessment of publication bias
There was an insufficient number of trials for us to assess
publication bias.
Adverse events
No postpartum morbidity (PPM) associated with ECS was
reported.
Discussion
Analysis of the effect of ECS for preventing MTCT of HBV
Four clinical trails were identified which evaluated the
efficacy of ECS for the prevention of MTCT of HBV. They
indicate ECS could significantly reduce the risk of MTCT.
With regard to postpartum morbidity (PPM), none of
these studies had reported the maternal morbidity or
infant morbidity associated with ECS. Therefore, based on
the included studies, the benefit of ECS outweighs the risk
of PPM among HBV-infected women. However, it is
important to point out that the risk/benefit ratio should
depend on the underlying rate of MTCT. With very low
rates of MTCT, the risks associated with ECS among HBV-
infected women may outweigh the benefits.
Currently, HBV DNA-positive is mostly considered the
direct index reflecting the infectivity of HBV. So we only
Analysis of the efficacy of ECS versus vaginal delivery for preventing MTCT of HBV Figure 1
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included HBV-infected women with HBV DNA-positive,
and also made neonates with HBV DNA-positive as the
outcome criteria. However, the detailed HBV DNA levels
in included HBV-infected women were not described,
except one study (Liu 2008), which included patients with
HBV DNA > 105 copy/ml. So we can't get adequate infor-
mation for the magnitude of infectivity, which may influ-
ence the effect of ECS for the prevention of MTCT of HBV
in this review. Subgroup analysis demonstrates that, HBV
DNA-positive either in neonate's umbilical blood or in
neonate's peripheral blood indicates the existence of HBV
infection, but false positive must be excluded as a result of
nonstandard collection of blood. According to principles
of medical ethics, we suggest neonate's umbilical blood
should be chosen for detection of HBV DNA, which can
largely relieve pains of newborns. But it must be per-
formed strictly to avoid pollution by maternal blood.
Limitations of this systematic review
The conclusions of this review must be considered with
great caution.
All the retrieved studies did not give adequate descriptions
of the methodology used, which may have misled us if we
had not clarified the details, for example, inclusion of
non-RCTs and classifying the trials into category B rather
than C. It was an exhausting but necessary process to inter-
view every primary trial author before deciding whether to
include these trials, when the methodological details were
not reported. Contacting authors by telephone was more
effective than writing to them because of a higher
response rate and left no time for the trial authors to make
up artificial details. However, even after confirmation of
true randomization, we found that the methodological
quality of these studies remained poor.
Allocation concealment is important in preventing selec-
tion bias. Each of the studies related to our question did
not use any approach to conceal the allocation process,
which could lead to a high risk of selection bias.
No blinding was conducted with either the participants or
the investigators, which led to a high risk of performance
bias. None of the studies mentioned blinding to the out-
come assessors, which promotes suspicion of detection
bias. Publication bias may exist as no primary articles
reporting negative results were found. No information of
numbers of withdrawals, dropouts, losses of follow up
may have led to high attrition bias in one study.
In addition, included studies of ECS among HBV-infected
women have been conducted exclusively in china. In
other countries, the risks and benefits associated with ECS
have been largely unexplored.
Conclusion
Implications for practice
Although studies of ECS showed a strong evidence of a
reduction in the risk of MTCT of HBV, methodological
concerns including lack of information on randomization
Subgroup analysis of the efficacy of ECS versus vaginal delivery for preventing MTCT of HBV Figure 2
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procedure, lack of allocation concealment, and lack of
blinding, make the role of ECS for preventing MTCT of
HBV uncertain.
Implications for research
More high quality controlled trials are required for assess-
ing the effects of ECS in comparison to vaginal delivery for
preventing MTCT of HBV. We suggest that well-designed
RCTs with adequate power to provide a definitive answer,
need be conducted. The randomization procedure should
be clearly described. Allocation concealment should be
emphasized and the approaches should be reported.
Blinding should be conducted, though this may be diffi-
cult. Additionally, more attention should be paid to PPM
associated with ECS.
Methods
Criteria for considering studies for this review
Types of studies
We included RCTs only.
Types of participants
HBV-infected Pregnant women with HBV DNA-positive
(HBV DNA > 103copies/ml) in sera of blood and their
babies.
Types of intervention
ECS versus vaginal delivery.
Types of outcome measures
Primary outcomes (HBV transmission-related)
HBV-infection in neonates: HBV DNA-positive in umbili-
cal blood or peripheral blood after birth.
Secondary outcomes (morbidities related to the actual
method of delivery)
(1)Maternal morbidity: types of maternal morbidity eval-
uated includes: febrile morbidity, endometritis, hemor-
rhage or severe anemia, pneumonia, and urinary tract
infections.
(2)Infant morbidity: types of infant morbidity evaluated
includes: respiratory morbidity (respiratory distress syn-
drome and transient tachypnea of the newborn) and skin
lacerations.
Search methods for identification of studies
Electronic searches
We searched the electronic databases as follows: Cochrane
Pregnancy and Childbirth Group's Trials Register (Janu-
ary, 2008), the Cochrane Central Register of Controlled
Trials (the Cochrane Library 2008, issue 1), PubMed
(1950 to 2008), EMBASE (1974 to 2008), Chinese Bio-
medical Literature Database (CBM) (1975 to 2008),
China National Knowledge Infrastructure (CNKI) (1979
to 2008), VIP database (1989 to 2008). We also searched
additional trials by scanning the reference lists of relevant
trials identified. The search strategy was iterative as fol-
lows:
1 HBV
2 HBV INFECT*
3 HBV INFECTIONS
4 HBV INFECTED
5 #1 OR #2 OR #3 OR #4
6 DELIVERY, OBSTETRIC
7 DELIVERY AND PREGNANCY
8 CAESAREAN SECTION
9 "MODE OF DELIVERY" AND PREGNANCY
10 #6 OR #7 OR #8 OR #9
11 INFANT MORTALITY
12 INFANT MORBIDITY
13 NEONATAL MORTALITY
14 NEONATAL MORBIDITY
15 MATERNAL MORTALITY
16 MATERNAL MORBIDITY
17 POSTPARTUM MORTALITY
18 POSTPARTUM MORBIDITY
19 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
OR#18
20 #5 AND #10 AND #19
21 (ANIMAL OF ANIMALS) NOT HUMAN
22 #20 NOT #21
Other search strategies
Organizations (including the World Health Organiza-
tion), individual researchers working in the field wereVirology Journal 2008, 5:100 http://www.virologyj.com/content/5/1/100
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contacted in order to obtain possible additional refer-
ences, unpublished trials, or ongoing trials, confidential
reports and raw data of published trials.
Selection of studies
The titles, abstracts and keywords of every record retrieved
were scanned to determine which were possibly relevant
to the review. Any record that appeared likely to meet the
inclusion criteria was obtained in full text. If there was any
doubt regarding eligibility from the information given in
the title and abstract, the full article was retrieved for clar-
ification. Differences in opinion between reviewers were
resolved by discussion.
Data extraction
Two review authors (ZX, MY) independently extracted
data concerning details of the study population, interven-
tions and outcomes using a standard data extraction form,
specifically designed for this review. We resolved differ-
ences in data extraction by consensus, and with reference
to the original article. If necessary, we sought information
from the authors of the primary studies. For dichotomous
outcomes, number of events and total number in each
group were extracted. For continuous outcomes, mean,
standard deviation and sample size of each group were
extracted.
Assessment of risk of bias in included trials
The risk of bias was assessed based largely on the quality
criteria specified by the Cochrane Handbook for System-
atic Reviews of Interventions 5.0.0 [22]. In particular, the
following factors were studied:
• Selection bias: a) was the randomization procedure ade-
quate? b) was the allocation concealment adequate?
￿ Performance bias: were the patients and people per-
forming the intervention blind to the intervention?
￿ Attrition bias: a) were withdrawals, dropouts and losses
of follow-up completely described? b) was analysis per-
formed by intention-to-treat?
￿ Detection bias: were outcome assessors blind to the
intervention?
Based on these criteria, studies were broadly divided into
the following three categories. This classification was used
as the basis of a sensitivity analysis. Additionally, we
intended to explore the influence of individual quality cri-
teria in a sensitivity analysis.
￿ A: all quality criteria met – low risk of bias.
￿ B: one or more of the quality criteria only partly met-
moderate risk of bias.
￿ C: one or more criteria not met – high risk of bias.
Each trial was assessed by two reviewers independently
(ZX, MY). Disagreements were resolved, where necessary,
by recourse to a third reviewer (YJ). In cases of disagree-
ment, the rest of the group were consulted and a judgment
was made based on consensus.
Data Analysis
Statistical analysis was carried out by using Review Man-
ager (version 4.2). Dichotomous data were presented as
relative risk (RR) and continuous outcomes as weighted
mean difference (WMD), both with 95% confidence
intervals (CI). The overall effect was tested by using Z
score with significance being set at P < 0.05. Heterogeneity
was tested by using the chi-squared statistic and I square
(I2) with significance being set at P < 0.1. Possible sources
of heterogeneity were to be assessed by sensitivity and
subgroup analyses. A fixed-effect model was to be used
when the studies in the subgroup were sufficiently similar
(P > 0.10, I2 < 50). A random effects model was to be used
in the summary analysis when there was heterogeneity
between the subgroups. Publication bias was to be tested
by using the funnel plot or other corrective analytical
method, depending on the number of clinical trials
included in the systematic review.
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